Strengthen your TRPML research with precise, robust, and high-quality data you can rely on

Data Card

Highly-validated screening assays developed by Metrion are capable of confidently identifying modulators of the lysosomal TRPML1 channel.

Highly-validated screening assays developed by Metrion are capable of confidently identifying modulators of the lysosomal TRPML1 channel. The TRPML1 variant that lacks the endo-lysosomal retention sequences (TRPML1-4A) is used, enabling the channel to express at the plasma membrane. As such, channel behaviour can be successfully characterised by:

  1. Conventional manual patch-clamp assays
  2. Automated patch-clamp (Qube 384) assays
  3. Fluorescence-based (FLIPR) assays

Read our case study: Development of TRPML1-4A assays across manual, automated patch-clamp, and fluorescence-based platforms

Contact Metrion to advance your preclinical drug discovery project


Recommended Publications
Latest Publications
Development of Automated Electrophysiology Assays for the Characterisation of Inhibitors Against Human HCN Ion Channels

We demonstrate the generation and validation of a stable CHO-hHCN2 cell line used as a cellular tool in the successful development of hHCN2 automated electrophysiology screening assays.

Seal enhancers on the Qube 384: An alternative to F

Metrion and Sophion collaborated to determine whether other insoluble salts can act as seal enhancers, or whether this property is unique to CaF2.

View All
Metrion Biosciences is a contract research organisation (CRO) specialising in high-quality preclinical drug discovery services.
magnifier
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram